Altered fractionation radiotherapy in lung cancer

Mauro Palazzi, Annamaria Cerrotta, Sergio Villa

Research output: Contribution to journalArticle


Clinical trials on altered fractionation radiotherapy (RT) regimens currently play a significant role in lung cancer, due to the importance of local control and to the disappointing therapeutic results in this disease. In non-small-cell lung cancer (NSCLC) two strategies are being actively investigated: hyperfractionation with a 'curative' aim, and hypofractionation with a palliative aim; in small-cell lung cancer (SCLC) altered fractionation seems to play a minor role at this moment. In this review paper the results of reported randomised trials are summarised and discussed. Conclusions may indicate that through hyperfractionation, particularly if accelerated, clinical outcome of non-metastatic NSCLC patients can be improved; data are however not sufficiently mature to advise its use outside controlled clinical trials. In the palliative setting, hypofractionation should be considered standard treatment.

Original languageEnglish
Pages (from-to)171-175
Number of pages5
Issue number2
Publication statusPublished - Mar 1998


  • Altered fractionation
  • Lung Cancer
  • Radiotherapy

ASJC Scopus subject areas

  • Cancer Research

Fingerprint Dive into the research topics of 'Altered fractionation radiotherapy in lung cancer'. Together they form a unique fingerprint.

  • Cite this

    Palazzi, M., Cerrotta, A., & Villa, S. (1998). Altered fractionation radiotherapy in lung cancer. Tumori, 84(2), 171-175.